Evidence map›Paper›PMID 18600183›Full record

ArticleJournal of immunotherapy (Hagerstown, Md. : 1997)2008

Inducing efficient cross-priming using antigen-coated yeast particles.

Shanshan W Howland, Takemasa Tsuji, Sacha Gnjatic, Gerd Ritter, Lloyd J Old, Karl Dane Wittrup

Open access · greenAbstract read
In one paragraph

Article in Journal of immunotherapy (Hagerstown, Md. : 1997), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Yeast oral vaccines against infectious diseases.Frontiers in microbiology · 2023
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Shanshan W HowlandDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Takemasa Tsuji
Sacha Gnjatic
Gerd Ritter
Lloyd J Old
Karl Dane Wittrup
Memorial Sloan Kettering Cancer Center · USMassachusetts Institute of Technology · USLudwig Cancer Research · US

Funding

Engineering and Analysis of T cell CD3 and IL2R SignalsR01AI065824 · NIAID · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI WITTRUP, KARL DANE · 2005 to 2008
$2.2M
NIAID NIH HHS AI065824NIAID NIH HHS R01 AI065824
6 · The paper itself

Abstract

Saccharomyces cerevisiae stimulates dendritic cells (DCs) and represents a promising candidate for cancer vaccine development. Effective cross-presentation of antigen delivered to DCs is necessary for successful induction of cellular immunity. Here, we present a yeast-based vaccine approach that is independent of yeast's ability to express the chosen antigen, which is instead produced separately and conjugated to the yeast cell wall. The conjugation method is site-specific (based on the SNAP-tag) and designed to facilitate antigen release in the DC phagosome and subsequent translocation for cross-presentation. We demonstrate that nonsite-specific chemical conjugation of the same protein hinders cross-presentation. Phagosomal antigen release was further expedited through the insertion of the invariant chain ectodomain as a linker, which is rapidly cleaved by Cathepsin S. The dose of delivered antigen was increased in several ways: by using yeast strains with higher surface amine densities, by using yeast hulls (cell wall fragments) instead of whole cells, and by conjugating multiple layers of antigen. The novel multilayer conjugation scheme takes advantage of Sfp phosphopantetheinyl transferase and remains site-specific; it enables the antigen dose to grow linearly with the number of layers. We show that whole yeast cells coated with 1 layer of the cancer-testis antigen NY-ESO-1 and yeast hulls bearing 3 layers were able to cross-prime naive CD8 T cells in vitro, with the latter resulting in higher frequencies of antigen-specific cells after 10 days. This cross-presentation-efficient antigen conjugation scheme is not limited to yeast and can readily be applied toward the development of other particulate vaccines.

Indexed as

Escherichia coliSaccharomyces cerevisiaeAminationAntigen PresentationAntigens, Differentiation, B-LymphocyteAntigens, NeoplasmAntigens, ViralCancer VaccinesCD8-Positive T-LymphocytesCell DifferentiationCoated VesiclesCross-PrimingCytomegalovirusDendritic CellsHistocompatibility Antigens Class IIHumansAntigens, Differentiation, B-LymphocyteAntigens, NeoplasmAntigens, ViralCancer VaccinesCTAG1B protein, humancytomegalovirus matrix protein 65kDaHistocompatibility Antigens Class IIInterferon-gammainvariant chainMembrane ProteinsO(6)-Methylguanine-DNA MethyltransferasePeptide FragmentsPhosphoproteinsRecombinant Fusion ProteinsViral Matrix Proteins

Identifiers

PMID18600183
PMCPMC2820298
OpenAlexW2060768499

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.